Page last updated: 2024-10-27

flumazenil and Congenital Adrenal Hyperplasia

flumazenil has been researched along with Congenital Adrenal Hyperplasia in 2 studies

Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.
flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Dumic, KK1
Grubic, Z1
Kusec, V1
Braovac, D1
Gotovac, K1
Vinkovic, M1
Vucinic, M1
Dumic, M1
Kocova, M1
Anastasovska, V1
Petlichkovski, A1
Falhammar, H1

Other Studies

2 other studies available for flumazenil and Congenital Adrenal Hyperplasia

ArticleYear
The prevalence and genotype of 21-hydroxylase deficiency in the Croatian Romani population.
    Frontiers in endocrinology, 2023, Volume: 14

    Topics: Adrenal Hyperplasia, Congenital; Croatia; Cross-Sectional Studies; Genotype; Humans; Prevalence; Rom

2023
First insights into the genetics of 21-hydroxylase deficiency in the Roma population.
    Clinical endocrinology, 2021, Volume: 95, Issue:1

    Topics: Adrenal Hyperplasia, Congenital; Genotype; Humans; Mutation; Roma; Steroid 21-Hydroxylase

2021